Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | terminated | Phase 1 | 111 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 15, 2022 | clinicaltrials |
| NCT02400814 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 27 | Megan Daly, MDOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03321747 | Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung | terminated | Phase 1 | 13 | Indiana UniversityOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 12, 2022 | clinicaltrials |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | terminated | Phase 1 | 2 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | terminated | Phase 1 | 10 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT03054038 | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 22 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | terminated | Phase 1 | 1 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 1 | 16 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer(ILIAD) | terminated | Phase 1 | 21 | MendusINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01455389 | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | terminated | Phase 1 / Phase 2 | 25 | Genprex, Inc.INDUSTRY | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03255083 | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 13 | Daiichi SankyoINDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT03990077 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | terminated | Phase 1 | 2 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | Dec 10, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | terminated | Phase 1 | 24 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Aug 27, 2021 | clinicaltrials |
| NCT02349633 | Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) | terminated | Phase 1 / Phase 2 | 65 | PfizerINDUSTRY | 4 | Jun 10, 2021 | clinicaltrials |
| NCT03597009 | A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion | terminated | Phase 1 / Phase 2 | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT01212627 | Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer | terminated | Phase 1 | 12 | Angela Taber MDOTHER | 1 | Feb 16, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | terminated | Phase 1 | 6 | National Health Research Institutes, TaiwanOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma | terminated | Phase 1 / Phase 2 | 60 | Regeneron PharmaceuticalsINDUSTRY | 2 | Dec 10, 2020 | clinicaltrials |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 5 | Herlev HospitalOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) | terminated | Phase 1 | 2 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 16, 2020 | clinicaltrials |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy(PINNACLE) | terminated | Phase 1 / Phase 2 | 172 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT00866086 | Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors | terminated | Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04510415 | Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI | terminated | Phase 1 | 2 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 / Phase 2 | 612 | Clovis Oncology, Inc.INDUSTRY | 4 | Aug 4, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | AbbVieINDUSTRY | 5 | Jul 17, 2020 | clinicaltrials |
| NCT03330834 | CAR-T Cell Immunotherapy for Advanced Lung Cancer | terminated | Phase 1 | 1 | Sun Yat-sen UniversityOTHER | 1 | Jul 13, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 15, 2022source: clinicaltrials